BioAtla IPO Presentation Deck

Upcoming Inflection Points Expected Multiple Near-term Regulatory, Clinical Safety and Efficacy Read-outs Program BA3011 (AXL) BA3021 (ROR2) BA3071 (CTLA-4) Bi- specific 1H Note: "Ovarian IT not shown 2020 2H 1H 2021 2H Phase 2 in Soft Tissue & Bone Sarcoma Phase 2 NSCLC (n=20) Phase 2 Interim Data Readout¹ Phase 2 Interim Data Readout¹ Phase 2 in NSCLC & Melanoma Phase 2 Interim Data Readout¹ Phase 1 Dose Escalation 1H IND Filling BA3182 2022 2H bicatla Phase 2 Pivotal Data Readout Phase 2 Data Readout IND Filing BA3142. EGFR. Nectin-4 27

View entire presentation